Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
J-Pharma Initiates PI Trial of LAT1 Inhibitor
The bioventure company J-Pharma Co. Ltd. has initiated a PI clinical trial of JPH203, a selective inhibitor of L-type amino acid transporter 1. According to the company, no anticancer drug with this mechanism of action has been developed, so this…
To read the full story
Related Article
- J-Pharma Goes Public on TSE, Eyes Licensing of LAT1 Inhibitors
March 26, 2026
- J-Pharma’s Biliary Tract Cancer Med Hits Mark in Japan PII Study
January 24, 2023
- Ohara Obtains Exclusive Rights to Biliary Tract Cancer Drug
April 26, 2019
BUSINESS
- MSD Files Oral PCSK9 Inhibitor Enlicitide in Japan
September 15, 2026
- Takeda’s Zasocitinib Gets FDA Priority Review in Plaque Psoriasis
September 15, 2026
- Asahi Kasei Starts Pediatric Cresemba PII in Japan
September 15, 2026
- Santen Files Myopia Drug Ryjusea in China
September 15, 2026
- Moderna Ratchets Up Oncology Drive with Cancer Vaccine PIII Win
September 15, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…